GL1X · GenesisL1 explorer

MolNFT v1 · #39688 · protein

Novel thiazolones as HCV NS5B polymerase inhibitors: further designs, synthesis, sar and X-ray complex structure

2I1R · RNA-directed RNA polymerase (NS5B) (P68): “Novel thiazolones as HCV NS5B polymerase inhibitors: further designs, synthesis, sar and X-ray complex…”. X-ray diffraction, 1 ligand (VXR), 15 pockets (best druggability 0.80). MolNFT v1…

PDB
2I1R
Type
protein
Length
1,120 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
RNA-directed RNA polymerase (NS5B) (P68)
EC
2.7.7.48
UniProt
P26663
Ligands
VXR
Pockets
15 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARNA-directed RNA polymerase (NS5B) (P68) (EC 2.7.7.48)protein55948% helix, 16% strandP26663
BRNA-directed RNA polymerase (NS5B) (P68) (EC 2.7.7.48)protein56148% helix, 16% strandP26663

Ligands and binding sites

  • VXR · (5Z)-5-[(5-ethyl-2-furyl)methylene]-2-{[(S)-(4-fluorophenyl)(1h-tetrazol-5-yl)methyl]amino}-1,3-thiazol-4(5H)-one · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110630.800.8180empty
210720.800.8179empty
311250.760.7957empty
4950.490.8217empty
5940.470.8119empty

Interfaces

1 interface between chains.

  • A–B · 543 Ų buried · 11 hydrogen bonds · protein-protein

Compared structures

  • 2I1R · Novel Thiazolones as HCV NS5B Polymerase Inhibitors: Further Designs, Synthesis, SAR and… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.